SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein
COVID-19 Nucleocapsid Research.
Cat: 40588-V08B
SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein: 製品情報
純度
> 90 % as determined by SDS-PAGE.
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
活性
Testing in progress
タンパク質の構築
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein (YP_009724397.2(335Gly/Ala)) (Met1-Ala419) was expressed with a polyhistidine tag at the C-terminus.
NP No.
発現ホスト
Baculovirus-Insect Cells
種
2019-nCoV
予測N末端
Met 1
分子量
The recombinant SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein (His tag) consists of 430 amino acids and predicts a molecular mass of 47.08 kDa.
バッファー
Lyophilized from sterile 20mM Tris, 500mM NaCl, pH8.0, 10%glycerol
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
配送
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
安定性 & 保存条件
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
再構成
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein: 画像
SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein: 別名
coronavirus NP Protein, 2019-nCoV; coronavirus Nucleocapsid Protein, 2019-nCoV; coronavirus Nucleoprotein Protein, 2019-nCoV; cov np Protein, 2019-nCoV; ncov NP Protein, 2019-nCoV; NCP-CoV Nucleocapsid Protein, 2019-nCoV; novel coronavirus NP Protein, 2019-nCoV; novel coronavirus Nucleocapsid Protein, 2019-nCoV; novel coronavirus Nucleoprotein Protein, 2019-nCoV; np Protein, 2019-nCoV; nucleocapsid Protein, 2019-nCoV; Nucleoprotein Protein, 2019-nCoV
Coronavirus Nucleocapsid 背景情報
Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. Coronavirus nucleoproteins localize to the cytoplasm and the nucleolus, a subnuclear structure, in both virus-infected primary cells and in cells transfected with plasmids that express N protein. The coronavirus N protein is required for coronavirus RNA synthesis and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is the most abundant protein of coronavirus. During virion assembly, N protein binds to viral RNA and leads to the formation of the helical nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. Because of the conservation of the N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool.
参考文献
- 1.Van Boheemen S, et al. (2012), MBio. 3(6):e00473-12.
- Bisht H. et al., 2004, Proc Natl Acad Sci. 101 (17): 6641-6.
- Li W. et al., 2005, Science. 309 (5742): 1864-8.
2019-nCoV Coronavirus Nucleocapsid タンパク質
HCoV-OC43 Coronavirus Nucleocapsid タンパク質
HCoV-NL63 Coronavirus Nucleocapsid タンパク質
HCoV-229E Coronavirus Nucleocapsid タンパク質
SARS Coronavirus Nucleocapsid タンパク質
HCoV-HKU1 Coronavirus Nucleocapsid タンパク質
MERS-CoV Coronavirus Nucleocapsid タンパク質
-
Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen MicroarrayAuthorDe Assis, RR;Jain, A;Nakajima, R;Jasinskas, A;Year2020JournalBioRxiv
-
Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen MicroarrayAuthorKhan, S;Nakajima, R;Jain, A;De Assis, RR;Jasinskas, A;Year2020JournalBioRxiv
-
COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in salivaAuthorRandad, PR;Pisanic, N;Kruczynski, K;Manabe, YC;Year2020JournalmedRxiv
-
Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patientsAuthorSun, B;Feng, Y;Mo, X;Zheng, P;Wang, Q;Li, P;Peng, P;Liu, X;Chen, Z;Huang, H;Zhang, F;Luo, W;Niu, X;Hu, P;Wang, L;Peng, H;Huang, Z;Feng, L;Li, F;Zhang, F;Li, F;Zhong, N;Chen, L;Year2020JournalEmerg Microbes Infect
-
SARS-CoV-2 Antibody responses do not predict COVID-19 disease severityAuthorPhipps, WS;SoRelle, JA;Li, QZ;Mahimainathan, L;Year2020JournalmedRxivApplicationIgM testing
-
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 infectionAuthorSimon, D;Tascilar, K;Krönk, G;Kleyer, A;Zaiss, M;Heppt, F;Meder, C;Atreya, R;Klenske, E;Dietrich, P;Abdullah, A;Kliem, T;Corte, G;Morf, H;Leppkes, M;Kremer, A;Ramming, A;Pachowsky, M;Schuch, F;Ronneberger, M;Kleinert, S;Maier, C;Hueber, A;Manger, K;Manger, B;Berking, C;Tenbusch, M;Überla, K;Sticherling, M;Neurath, M;Schett, G;Year2020JournalResearch Square
-
SARS-CoV-2 environmental contamination associated with persistently infected COVID-19 patientsAuthorLei, H;Ye, F;Liu, X;Huang, Z;Ling, S;Jiang, Z;Cheng, J;Huang, X;Wu, Q;Wu, S;Xie, Y;Xiao, C;Ye, D;Yang, Z;Li, Y;Leung, NHL;Cowling, BJ;He, J;Wong, SS;Zanin, M;Year2020JournalInfluenza Other Respir Viruses
-
SARS-CoV-2-specific antibody detection for sero-epidemiology: a multiplex analysis approach accounting for accurate seroprevalenceAuthorden Hartog, G;Schepp, R;Kuijer, M;GeurtsvanKessel, C;van Beek, J;Rots, N;Koopmans, M;van der Klis, F;van Binnendijk, R;Year2020JournalmedRxiv
-
COVID-19 Severity Correlates with Weaker T Cell Immunity, Hypercytokinemia and Lung Epithelium InjuryAuthorWang, Z;Yang, X;Zhou, Y;Sun, J;Liu, X;Zhang, J;Mei, X;Zhong, J;Zhao, J;Ran, P;Year2020JournalAm. J. Respir. Crit. Care Med.Applicationneutralization test
-
SARS-CoV-2 surveillance for a non-human primate breeding research facilityAuthorYee, JL;Van Rompay, KKA;Carpenter, AB;Nham, PB;Halley, BM;Iyer, SS;Hartigan-O'Connor, DJ;Miller, CJ;Roberts, JA;Year2020JournalJ. Med. Primatol.
-
A rapidly adaptable biomaterial vaccine for SARS-CoV-2AuthorLangellotto, F;Seiler, B;Yu, J;Cartwright, M;White, D;Yeager, C;Super, M;Doherty, E;Barouch, D;Mooney, D;Year2020JournalbioRxiv
-
Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications on COVID-19 immunityAuthorMcAndrews, KM;Dowlatshahi, DP;Dai, J;Becker, LM;Hensel, J;Snowden, LM;Leveille, JM;Brunner, MR;Holden, K;Hopkins, NS;Harris, A;Kumpati, JJ;Whitt, MA;Lee, JJ;Ostrosky-Zeichner, L;Papanna, R;LeBleu, V;Allison, J;Kalluri, R;Year2020JournalJCI Insight
-
Accurate Serology for SARS-CoV-2 and common Human Coronaviruses using a Multiplex ApproachAuthorvan Tol, S;Mögling, R;Li, W;Godeke, GJ;Swart, A;Bergmans, B;Brandenburg, A;Kremer, K;Murk, JL;van Beek, J;Wintermans, B;Reimerink, J;Bosch, BJ;Reusken, C;Year2020JournalEmerg Microbes Infect
If you couldn't find the specific citation, you can:
